CRVS
NASDAQ
$14.10
Corvus Pharmaceuticals Inc (CRVS)
Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. The company is headquartered in Burlingame, California.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $33.33 (+136.38%)
Market Cap
$1.25B
EPS 5Y CAGR
+53.96%
Free Cash Flow Yield
-2.80%
Beta (5Y)
0.75
Price Chart
Valuation
Market Cap$1.25B
P/B5.23
Profitability
Total Revenue (TTM)$3.76M
EBITDA-$48M
EPS-$0.57
Financial Health
Free Cash Flow Yield-2.80%
Growth & Risk
EPS 5Y CAGR+53.96%
FCF 5Y CAGR+0.49%
Beta (5Y)0.75
Sharpe Ratio1.16